Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 6Plasma cell 2

Conditions

Multiple Myeloma 3Vascular Diseases 2Paraproteinemias 2Lymphoproliferative Disorders 2Immunoproliferative Disorders 2Hemostatic Disorders 2Hemorrhagic Disorders 2Hematologic Diseases 2Blood Coagulation Disorders 2Neoplasms, Plasma Cell 1

Interventions

Bortezomib 4dacetuzumab 2Lenalidomide 2Dexamethasone 2isatuximab 1ficlatuzumab 1Vorinostat 1KW-2478 1Hsp90 inhibitor KU757 1Erlotinib Hydrochloride 1Calcium Dobesilate 1CLR1404 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Immunoproliferative Disorders × dacetuzumab × Plasma cell × Clear all
NCT00079716 2014-12-18

Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma

Seagen Inc.

Phase 1 Completed
44 enrolled
LymphoidPlasma cell

Blood Coagulation Disorders, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

NCT00525447 2014-10-09

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

Seagen Inc.

Phase 1 Completed
36 enrolled
LymphoidPlasma cell

Blood Coagulation Disorders, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡